Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: A systematic review of the literature

Texas Heart Institute Journal

Volumn 37, Issue 1, 2010, Pages 25-39

  Madjid, Mohammad ^a   Ali, Muzammil ^a   Willerson, James T ^a  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Atherosclerosis prevention control; Biological markers blood; C reactive protein; Case control studies; Cohort studies; Epidemiology; Inflammation; Lipoprotein associated phospholipase A2; Phospholipases A2; Treatment outcome

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL RESEARCH; REVIEW; RISK ASSESSMENT; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; YOUNG ADULT;

EID: 77950418219     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290(7):898-904.
2. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996;124 Suppl:S1-9.
3. Ross R. Atherosclerosis- an inflammatory disease. N Engl J Med 1999;340(2):115-26.
4. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004;109(21 Suppl 1):II2-10.
5. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98(8):731-3.
6. Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004;44(10):1945-56.
7. Ali M, Madjid M. Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target. Future Cardiol 2009;5(2):159-73.
8. Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimpf B, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995;374(6522): 549-53.
9. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005;25(5):923-31.
10. Karabina SA, Liapikos TA, Grekas G, Goudevenos J, Tselepis AD. Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions. Biochim Biophys Acta 1994;1213(1):34-8.
11. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005;51(12):2264-73.
12. Subbanagounder G, Leitinger N, Schwenke DC, Wong JW, Lee H, Rizza C, et al. Determinants of bioactivity of oxidized phospholipids. Specific oxidized fatty acyl groups at the sn-2 position. Arterioscler Thromb Vasc Biol 2000;20(10):2248-54.
13. Subbanagounder G, Wong JW, Lee H, Faull KF, Miller E, Witztum JL, Berliner JA. Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1beta. J Biol Chem 2002;277(9):7271-81.
14. Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K, Nagahiro S. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 2002;22(10):1649-54.
15. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001;103(15):1955-60.
16. Hakkinen T, Luoma JS, Hiltunen MO, Macphee CH, Milliner KJ, Patel L, et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999;19(12):2909-17.
17. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, Virmani R. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006;26(11):2523-9.
18. Sen A, Buja LM, Willerson JT, Chien KR. Membrane phospholipid metabolism during myocardial ischaemia: past, present and future. Basic Res Cardiol 1987;82 Suppl 1:121-5.
19. Chien KR, Willerson JT, Buja LM. Phospholipid alterations and membrane injury during myocardial ischemia. Adv Myocardiol 1985;5:347-53.
20. Watanabe J, Marathe GK, Neilsen PO, Weyrich AS, Harrison KA, Murphy RC, et al. Endotoxins stimulate neutrophil adhesion followed by synthesis and release of platelet-activating factor in microparticles. J Biol Chem 2003;278(35):33161-8.
21. Memon RA, Fuller J, Moser AH, Feingold KR, Grunfeld C. In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response. Am J Physiol 1999; 277(1 Pt 2):R94-103.
22. Castro Faria Neto HC, Stafforini DM, Prescott SM, Zimmerman GA. Regulating inflammation through the anti-inflammatory enzyme platelet-activating factor-acetylhydrolase. Mem Inst Oswaldo Cruz 2005;100 Suppl 1:83-91.
23. Morgan EN, Boyle EM Jr, Yun W, Kovacich JC, Canty TG Jr, Chi E, et al. Platelet-activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury. Circulation 1999;100(19 Suppl):II365-8.
24. Theilmeier G, De Geest B, Van Veldhoven PP, Stengel D, Michiels C, Lox M, et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/-mice. FASEB J 2000;14 (13):2032-9.
25. Kume N, Gimbrone MA Jr. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest 1994;93(2):907-11.
26. Tselepis AD, John Chapman M. Inf lammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 2002;3(4):57-68.
27. Lanman RB, Wolfert RL, Fleming JK, Jaffe AS, Roberts WL, Warnick GR, McConnell JP. Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev Cardiol 2006;9(3):138-43.
28. Boekholdt SM, Keller TT, Wareham NJ, Luben R, Bingham SA, Day NE, et al. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol 2005;25(4):839-46.
29. Critical Appraisal Tools. Public Health Resource Unit. Available at: http://www.phru.nhs.uk/Pages/PHD/resources.htm
30. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005;26(2):137-44.
31. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 2006;113(14):1745-52.
32. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006;26(7):1586-93.
33. Corsetti JP, Rainwater DL, Moss AJ, Zareba W, Sparks CE. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem 2006;52(7):1331-8.
34. Jenny NS, Solomon C, Cushman M, Tracy RP, Nelson JJ, Psaty BM, Furberg CD. Lipoprotein-associated phospholipase A2 (Lp-PLA2) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study [abstract]. doi:10.1016/j.atherosclerosis/2009.09.021.
35. May HT, Horne BD, Anderson JL, Wolfert RL, Muhlestein JB, Renlund DG, et al. Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J 2006;152 (5):997-1003.
36. Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol 2006;26(11):2517-22.
37. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006;166(19):2073-80.
38. Persson M, Hedblad B, Nelson JJ, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 2007;27(6):1411-6.
39. Mockel M, Muller R, Vollert JO, Muller C, Danne O, Gareis R, et al. Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). Clin Res Cardiol 2007;96(9):604-12.
40. Sabatine MS, Morrow DA, O'Donoghue M, Jablonksi KA, Rice MM, Solomon S, et al. Prognostic utility of lipoproteinassociated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2007;27(11):2463-9.
41. Winkler K, Hoffmann MM, Winkelmann BR, Friedrich I, Schafer G, Seelhorst U, et al. Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Clin Chem 2007;53(8):1440-7.
42. Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 2007;27(8):1788-95.
43. May HT, Anderson JL, Horne BD, Pearson RR, Wolfert RL, Kolek MJ, et al. Lipoprotein-associated phospholipase A2 and high sensitivity C-reactive protein levels and the prediction of cardiovascular risk among coronary artery disease patients with differing clinical patients [abstract]. Circulation 2007;116:II 799-800.
44. Daniels LB, Laughlin GA, Sarno MJ, Bettencourt R, Wolfert RL, Barrett-Connor E. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J Am Coll Cardiol 2008;51(9):913-9.
45. Raichlin E, McConnell JP, Bae JH, Kremers WK, Lerman A, Frantz RP. Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients. Transplantation 2008;85(7):963-8.
46. Simon T. Impact of circulating secretory phospholipase A2 (sPLA2) and lipoprotein-associated phospholipase A2 (Lp-PLA2) activities on 6 months-survival, recurrent AMI and incident stroke in patients with AMI [poster]. Presented at: ESC Congress 2008; Munich, Germany.
47. Tsimikas S, Willeit J, Knoflach M, Mayr M, Egger G, Notdurfter M, et al. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J 2009;30(1):107-15.
48. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343(16):1148-55.
49. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001;38(5):1302-6.
50. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004;110(14):1903-8.
51. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004;109(7):837-42.
52. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005;111(5):570-5.
53. Hatoum IJ, Nelson JJ, Rexrode K, Manson J, Rimm EB. Lipoprotein-associated phospholipase A2 and myocardial infarction in women [abstract]. Circulation 2007;116:II-818.
54. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000; 150(2):413-9.
55. Blankenberg S, Stengel D, Rupprecht HJ, Bickel C, Meyer J, Cambien F, et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res 2003;44(7):1381-6.
56. Khuseyinova N, Imhof A, Rothenbacher D, Trischler G, Kuelb S, Scharnagl H, et al. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis 2005;182(1):181-8.
57. Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M, et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study [published erratum appears in Circulation 2005;111 (24):e444]. Circulation 2005;111(8):980-7.
58. Johnston N, Jernberg T, Lagerqvist B, Siegbahn A, Wallentin L. Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers. Am J Cardiol 2006;97(5):640-5.
59. Oldgren J, James SK, Siegbahn A, Wallentin L. Lipoproteinassociated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur Heart J 2007;28(6):699-704.
60. Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2008;28(6):1172-8.
61. Furberg CD, Nelson JJ, Solomon C, Cushman M, Jenny NS, Psaty BM. Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study. J Am Geriatr Soc 2008;56(5):792-9.
62. Muzzio ML, Miksztowicz V, Brites F, Aguilar D, Repetto EM, Wikinski R, et al. Metalloproteases 2 and 9, Lp-PLA(2) and lipoprotein profile in coronary patients. Arch Med Res 2009;40(1):48-53.
63. Stephens CJ, Graham RM, Sturm MJ, Richardson M, Taylor RR. Variation in plasma platelet-activating factor degradation and serum lipids after acute myocardial infarction. Coron Artery Dis 1993;4(2):187-93.
64. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350(14):1387-97.
65. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med 2006;166(13):1368-73.
66. Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999;19(10):2348-54.
67. Tracy RP. Inf lammation markers and coronary heart disease. Curr Opin Lipidol 1999;10(5):435-41.
68. Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008;101(12A):51F-57F.
69. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009;119(17):2408-16.
70. Madjid M, Aboshady I, Awan I, Litovsky S, Casscells SW. Influenza and cardiovascular disease: is there a causal relationship? Tex Heart Inst J 2004;31(1):4-13.
71. Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, et al. Effects of the direct lipoproteinassociated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118(11): 1172-82.
72. Mohler ER 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2008;51(17): 1632-41.
73. Saougos VG, Tambaki AP, Kalogirou M, Kostapanos M, Gazi IF, Wolfert RL, et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007;27(10):2236-43.
74. Labarthe DR. Epidemiology and prevention of cardiovascular diseases: a global challenge. Gaithersburg (MD): Aspen Publishers; 1998.